Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
Rhea-AI Summary
Whitehawk Therapeutics (Nasdaq: WHWK) said Dave Lennon, PhD, President and CEO, will appear in a virtual fireside chat on Thursday, April 23, 2026 at 3:00 PM ET as part of the Jones Trading Post-AACR Fireside Chat Series.
A live webcast is accessible via the company investor relations website and will be available for replay for approximately 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – WHWK
In the Apr 17 session, WHWK declined 2.84%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.1% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.3x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 10 | Scientific data update | Positive | -4.5% | Real-world data confirming MUC16 as a strong ADC target in gynecologic cancers. |
| Mar 17 | Pipeline conference plans | Positive | -3.5% | Plans to present three ADC preclinical programs with encouraging efficacy and safety signals. |
| Mar 12 | Earnings and pipeline | Neutral | -2.7% | Year-end cash of $145.7M, ongoing Phase 1 recruitment and planned IND for HWK-206. |
| Feb 26 | Investor conferences | Neutral | -1.5% | Participation in three early-March investor conferences with webcast access for investors. |
| Feb 18 | Conference presentation | Neutral | +2.0% | Announcement of CEO presentation at Oppenheimer healthcare conference with webcast replay. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent scientifically positive and conference-related news often coincided with negative price reactions, suggesting a pattern of weakness around otherwise constructive updates.
Over the last two months, Whitehawk reported multiple ADC-focused milestones and events. On Feb 18, it announced an Oppenheimer conference appearance, followed by additional investor conferences on Feb 26. The Mar 12 update detailed $145.7M in cash and a $20.6M full-year 2025 net loss, alongside active Phase 1 programs. Subsequent scientific presentations at AACR and SGO in March and April highlighted its ADC portfolio and MUC16 targeting, yet shares generally traded down after these disclosures.
Key Terms
antibody drug conjugate (adc) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the Jones Trading Post-AACR Fireside Chat Series on Thursday, April 23, 2026, at 3 PM ET.
A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact:
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-jones-trading-post-aacr-fireside-chat-series-302745213.html
SOURCE Whitehawk Therapeutics, Inc.